Clinical trial · Interventional
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
NCT07081022CI-TRIAL-00125890active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B-cell Non-Hodgkin's Lymphoma | B-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| JS203 combined with lenalidomide | Drug | — | UNRESOLVED |
| JS203 in combination with gemcitabine and oxaliplatin | Drug | — | UNRESOLVED |
| JS203 in combination with ifosfamide, carboplatin and etoposide | Drug | — | UNRESOLVED |
| JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- type
- EXPERIMENTAL
- label
- DLBCL-Gemox
- description
- In participants with relapsed/refractory diffuse large B cell lymphoma ineligible for ASCT
- interventionNames
- Drug: JS203 in combination with gemcitabine and oxaliplatin
- type
- EXPERIMENTAL
- label
- DLBCL-ICE
- description
- In participants with relapsed/refractory diffuse large B cell lymphoma intended for ASCT
- interventionNames
- Drug: JS203 in combination with ifosfamide, carboplatin and etoposide
- type
- EXPERIMENTAL
- label
- DLBCL- RCHOP
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be enrolled： * Age range: 18 to 80 years old (inclusive), both male and female are acceptable； * ECOG: 0-2； * B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed； * At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening； Exclusion Criteria: * A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)； * Previously received CD20-CD3 bispecific antibody treatment； * Previous allogeneic hematopoietic stem cell transplantation； * Previous solid organ transplantation； * History of autoimmune diseases； * Patients with a history of macrophage activation syndrome (MAS)/ hemophagocytic lymphohistiocytosis (HLH)； * Patients with a history of progressive multifocal leukoencephalopathy (PML)； * A known or suspected history of CNS lymphoma (including primary or secondary)； * There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage)；
References
Publications (0)
Data not yet available
No reference posted for this study.